Pharmaceutical

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

Nov 5, 2024 - 06:00
Syndax agrees funding with Royalty Pharma for Niktimvo US sales
Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.
Read the original article

Tags:

Previous Article

EC fines Teva $502m over multiple sclerosis treatment Copaxone practices

Next Article

Injectables manufacturing ushers in a new era of accessibility

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rona Therapeutics gains Series A+ funds for siRNA pipeline expansion

Rona Therapeutics gains Series A+ funds for siRNA pipel...

Jul 20, 2024

Polio transmission was supposed to end by 2023. A new report explains why it won’t.

Polio transmission was supposed to end by 2023. A new r...

Sep 16, 2023

Kymera’s protein degrader starts Phase II trial in atopic dermatitis

Kymera’s protein degrader starts Phase II trial in atop...

Dec 8, 2023